ROR/ELSI and EHRI workgroups were highlighted. Tracy McGregor, the concept sheet author, will circulate a revised concept sheet to both WGs prior to resubmitting it for approval. • The workgroup reviewed the RoR/ELSI data collection of what is being returned, how results are being returned, which providers will get the results, and which tools will disclose the results. The workgroup clarified that they are incorporating participants’ past medical histories into their data collection. " • General process for returning results is: clinical report from CSGs via GeneInsight Variant Clinical " " " Contextualization disclose results to participants disclose negative results to participants Assess impact on system, provider and participant. Site differences present opportunity to inform medical community broadly about practice range. • The workgroup noted potential internal collaborations with EHRI (results reporting tools), Clinical Annotation (variant clinical actionability determination) and Outcomes Workgroups (process outcomes from variant information return in the clinic), and external collaborations with CSER and IGNITE Networks, both of which encompass efforts in clinical implementation of clinical sequencing and genomics data. ACTION ITEM: RoR/ELSI group to complete RoR survey and determine eMERGE RoR standards ACTION ITEM: Starting with ClinGen recommendations, the RoR/ELSI WG with the Clinical Actionability WG will develop an eMERGE Actionability Assessment protocol. ACTION ITEM: Develop a repository of standardized surveys, potentially accessed online through REDCap. ACTION ITEM: Tracy McGregor will edit concept sheet NT175 and distribute to the RoR/ELSI and EHRI workgroups, who are collaborating on this project. ACTION ITEM: RoR/ELSI will attend some CSER workgroup meetings when there is overlap, especially in genetic education and for CSER’s Act-ROR Case presentations. A Proposed eMERGE 3 Ancillary Study of Impact of Return of Genomic Results to Health Care Providers– Ingrid Holm & Iftikhar Kullo • Background & Impact: Little is known of healthcare providers’ perspective on the desirability, utility, actionability, and meaning of incorporating genomic sequencing results into clinical care. eMERGE is a good platform to study this due to the size of the Network’s biobank population and resulting large scale return of genomic sequencing results, expertise, and history of success. • Study aims: 1) HCP’s views on clinical genomic sequencing, 2) clinical utility of genomic sequencing results – expected and actual, 3) attitudes towards accessing genomic sequence results in the EHR. • Survey approach: baseline survey offered to HCP with patients enrolled in eMERGE III undergoing sequencing, one- month survey post-receiving results on patient questioning intent of use of information and attitudes regarding accessing genomic sequence results in EHR, and six-month survey post-receiving results on patient to assess actual use of information. • Ingrid and Iftikhar discussed submitting a coordinated administrative supplement proposal to the NHGRI to conduct the study. Partnering with other groups (International Collaboration for Clinical Genomics (ICCG) or the American Medical Association (AMA)) was discussed.